Sales reps' presence tied to heart stent use
NEW YORK (Reuters Health) - Having sales representatives from medical device companies at hospitals may influence which products doctors use and ultimately drive up costs, according to a new study from Canada. Researchers found that doctors were more likely to use a company's drug-coated heart stent when one of its sales representatives visited their hospital, which resulted in about a $250 higher bill per case. "We need to evaluate carefully any interactions with medical industry to ensure that we minimize an effect on our decision making process," wrote Dr. Shahar Lavi, the study's lead author, in an email to Reuters Health.
- NFP Hospitals' Revenue Growth at 'All-Time Low'
- Transforming Cancer Care
- CNO Leads $1M Charge for New Scrubs, Uniforms
- Acute Kidney Injury Gets New Focus
- Interventional Radiology No Longer a Sub-Specialty
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013
- Sharp HealthCare Leaves Pioneer ACO Program
- mHealth Tackles Readmissions
- Proton Beam Therapy Poised for Growth in US
- MA an Insurance Proving Ground for Providers